Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 NICE guidelines on anti-tumor necrosis factor therapy for RA.

× No keyword cloud information.

15 in total

1. National Institute for Clinical Excellence and its value judgments.

Authors: Michael D Rawlins; Anthony J Culyer
Journal: BMJ Date: 2004-07-24

Review 2. Switching between biological agents.

Authors: R F van Vollenhoven
Journal: Clin Exp Rheumatol Date: 2004 Sep-Oct Impact factor: 4.473

3. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register.

Authors: J A Karlsson; L E Kristensen; M C Kapetanovic; A Gülfe; T Saxne; P Geborek
Journal: Rheumatology (Oxford) Date: 2008-02-27 Impact factor: 7.580

Review 4. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Authors: Y-F Chen; P Jobanputra; P Barton; S Jowett; S Bryan; W Clark; A Fry-Smith; A Burls
Journal: Health Technol Assess Date: 2006-11 Impact factor: 4.014

5. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial.

Authors: Y P M Goekoop-Ruiterman; J K de Vries-Bouwstra; C F Allaart; D van Zeben; P J S M Kerstens; J M W Hazes; A H Zwinderman; H K Ronday; K H Han; M L Westedt; A H Gerards; J H L M van Groenendael; W F Lems; M V van Krugten; F C Breedveld; B A C Dijkmans
Journal: Arthritis Rheum Date: 2005-11

6. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials.

Authors: Angela Zink; Anja Strangfeld; Matthias Schneider; Peter Herzer; Franka Hierse; Maria Stoyanova-Scholz; Siegfried Wassenberg; Andreas Kapelle; Joachim Listing
Journal: Arthritis Rheum Date: 2006-11

Review 7. Switching anti-TNF-alpha agents: what is the evidence?

Authors: Alan R Erickson; Ted R Mikuls
Journal: Curr Rheumatol Rep Date: 2007-10 Impact factor: 4.592

8. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept.

Authors: Maya H Buch; Sarah J Bingham; Victoria Bejarano; Domini Bryer; Jo White; Richard Reece; Mark Quinn; Paul Emery
Journal: Arthritis Rheum Date: 2007-04-15

Review 9. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis.

Authors: P Barton; P Jobanputra; J Wilson; S Bryan; A Burls
Journal: Health Technol Assess Date: 2004-03 Impact factor: 4.014

10. Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug.

Authors: K L Hyrich; M Lunt; W G Dixon; K D Watson; D P M Symmons
Journal: Rheumatology (Oxford) Date: 2008-04-17 Impact factor: 7.580

3 in total

1. Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.

Authors: Jinoos Yazdany; R Adams Dudley; Randi Chen; Grace A Lin; Chien-Wen Tseng
Journal: Arthritis Rheumatol Date: 2015-06 Impact factor: 10.995

Review 2. Leveling the field in the treatment of rheumatoid arthritis with biologic therapies: equal access for equal efficacy.

Authors: Anthony S Russell; Wojtek P Olszynski; K S Davison; Cheryl Koehn; Boulos Haraoui
Journal: Clin Rheumatol Date: 2009-12-29 Impact factor: 2.980

Review 3. The effectiveness of anti-TNF-alpha therapies when used sequentially in rheumatoid arthritis patients: a systematic review and meta-analysis.

Authors: Suzanne Lloyd; Sylwia Bujkiewicz; Allan J Wailoo; Alex J Sutton; David Scott
Journal: Rheumatology (Oxford) Date: 2010-06-21 Impact factor: 7.580

3 in total